Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Acquisitions & Divestments (2017 - 2022)

Historic Change in Acquisitions & Divestments for Arcus Biosciences (RCUS) over the last 6 years, with Q3 2022 value amounting to $228.0 million.

  • Arcus Biosciences' Change in Acquisitions & Divestments rose 7093.26% to $228.0 million in Q3 2022 from the same period last year, while for Sep 2022 it was $608.8 million, marking a year-over-year decrease of 1819.3%. This contributed to the annual value of $690.1 million for FY2021, which is 12452.89% up from last year.
  • Arcus Biosciences' Change in Acquisitions & Divestments amounted to $228.0 million in Q3 2022, which was up 7093.26% from $169.0 million recorded in Q2 2022.
  • Arcus Biosciences' Change in Acquisitions & Divestments' 5-year high stood at $251.4 million during Q1 2021, with a 5-year trough of $25.6 million in Q1 2018.
  • For the 5-year period, Arcus Biosciences' Change in Acquisitions & Divestments averaged around $102.6 million, with its median value being $87.3 million (2019).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 41142.42% in 2021, then tumbled by 6267.7% in 2022.
  • Arcus Biosciences' Change in Acquisitions & Divestments (Quarter) stood at $42.3 million in 2018, then skyrocketed by 31.59% to $55.6 million in 2019, then skyrocketed by 209.42% to $172.0 million in 2020, then plummeted by 31.45% to $117.9 million in 2021, then soared by 93.36% to $228.0 million in 2022.
  • Its Change in Acquisitions & Divestments stands at $228.0 million for Q3 2022, versus $169.0 million for Q2 2022 and $93.8 million for Q1 2022.